Suchergebnisse - "Lenalidomide"

PubPharm (402)

1

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma : a single-arm phase II trial

enthalten in: Nature communications | 2024

von Park, C. | Lee, H. | Kang, K. | +16

2

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

enthalten in: Clinical therapeutics | 2019

von Telford, C. | Kabadi, S. | Abhyankar, S. | +4

3

Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia

enthalten in: Cancer | 2019

von Percival, M. | Estey, E.

4

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens

enthalten in: British journal of haematology | 2015

von Dytfeld, D. | Rosebeck, S. | Kandarpa, M. | +10

5

Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib : experience at an Australian Cancer Hospital

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2015

von Teh, B. | Worth, L. | Harrison, S. | +2

6

Development of extramedullary myeloma in the era of novel agents : no evidence of increased risk with lenalidomide-bortezomib combinations

enthalten in: British journal of haematology | 2015

von Varga, C. | Xie, W. | Laubach, J. | +13

CommentIn: Br J Haematol. 2015 Jun;169(6):763-5. - PMID 25825255

7

NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib

enthalten in: The Lancet. Oncology | 2015

von Burke, M. | George, E. | Adler, A.

8

Treatment-related symptom management in patients with multiple myeloma : a review

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2015

von Colson, K.

9

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide

enthalten in: Annals of hematology | 2015

von Lau, I. | Smith, D. | Aitchison, R. | +6

10

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

enthalten in: American journal of hematology | 2015

von Kastritis, E. | Roussou, M. | Gavriatopoulou, M. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[41]